^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Follicular Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Zevalin (ibritumomab tiuxetan) (CD20 inhibitor, Ionizing radiation emitter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Zevalin is indicated in adults...[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

    Excerpt:
    ...- CD20-positive disease...
    Trial ID:
    NCT00637832
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

    Excerpt:
    ...- CD20-positive disease confirmed by immunohistochemistry or flow cytometry...
    Trial ID:
    NCT00110149
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

    Excerpt:
    ...- Histologically confirmed CD20-positive B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:...
    Trial ID:
    NCT00397800
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.

    Excerpt:
    ......
    Trial ID:
    Z0105
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy.

    Excerpt:
    ...Central pathology review confirming the FL grade I-II diagnosis and CD20 positivity, andno evidence/evidence with an infiltration ...
    Trial ID:
    2006-004850-26
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Zevalin® First Line in Follicular Lymphoma

    Excerpt:
    ...- Lymphoma cells positive for CD20...
    Trial ID:
    NCT00772655
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

    Excerpt:
    ...- Central pathology review confirming the FL grade I-II diagnosis and CD20 positivity, and...
    Trial ID:
    FM+R-Z
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.

    Excerpt:
    ...• Histologically confirmed (according to WHO classification) CD 20 positive follicular lymphoma, grade 1, 2 or 3a, stage II, III or IV (with indication for treatment following local guidelines) of all FLIPI scores.• Age 18 years or older, for stem cell mobilisation analysis age 18-61 years• Having received 6-8 courses of 1st line R-CVP therapy• WHO performance status 0 to 2• Life expectancy of at least 6 months• PET positive partial remission on PET-CT scan after 6-8 R-CVP• Absolute neutrofil count (ANC) 1.5 x 109/l or higher• Platelet count of 150 x 109/l or higher• Hb > 6 mmol/l, (transfusion is allowed to achieve this)• Less than 25% bone marrow involvement after 6-8 R-CVP, measured by bone marrow biopsy. ...
    Trial ID:
    2009-012944-17